Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073
暂无分享,去创建一个
We read with interest the article recently published by Greenbaum et al. (1) describing the novel observation of the association of basophil count with change in C-peptide in recently diagnosed type 1 diabetes (T1D). The authors speculated that this association could be based on a compensatory attempt to deviate cells via interleukin-4 cytokine in the autoimmune response. In fact, by repeatedly activating basophils and mast cells using anti-FceR1, Hubner et al. (2) delayed the onset of diabetes in NOD mice. Thus, in accordance …
[1] C. Beam,et al. Fall in C-Peptide During First 2 Years From Diagnosis , 2012, Diabetes.
[2] M. Torrero,et al. Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice. , 2011, Clinical immunology.